US accelerated approval, Barth syndrome
On 19 September 2025 the US Food and Drug Administration granted accelerated approval to elamipretide as the first treatment for Barth syndrome in patients weighing at least 30 kg. The approval rests on improved strength of the muscle that straightens the knee, which the FDA calls reasonably likely to predict patient benefit. The FDA requires the manufacturer to run a further randomised, double-blind, placebo-controlled trial to confirm that benefit.
- Study type
- Regulatory-clinical source
- Population
- Approval for patients with Barth syndrome weighing at least 30 kg; United States only.
- Source
- 1 FDA, 2025
Limitation: US regulator only; the approval is conditional on a confirmatory trial and rests on a surrogate measure.
Limitations in full
US regulator only; the approval is conditional on a confirmatory trial and rests on a surrogate measure. Press announcement read; prescribing information not read.